Randomised, placebo-controlled, double-blind, parallele-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Carlo Antonio Barone

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

128 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'Randomised, placebo-controlled, double-blind, parallele-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer'. Insieme formano una fingerprint unica.

Pharmacology, Toxicology and Pharmaceutical Science